Pfizer is currently trading at Rs. 1110.00, up by 12.30 points or 1.12% from its previous closing of Rs. 1097.70 on the BSE.
The scrip opened at Rs. 1110.00 and has touched a high and low of Rs. 1110.00 and Rs. 1110.00 respectively.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1636.20 on 28-Jul-2011 and a 52 week low of Rs. 1071.55 on 30-Dec-2011.
Last one week high and low of the scrip stood at Rs. 1115.00 and Rs. 1087.70 respectively. The current market cap of the company is Rs. 3,312.00 crore.
The promoters holding in the company stood at 70.75% while Institutions and Non-Institutions held 9.23% and 20.02% respectively.
Pfizer has received an approval for incorporation of a wholly owned subsidiary in the state of Maharashtra, with a view to spin off its animal health business to such entity as a pre-step to subsequent sale to a wholly owned subsidiary of Pfizer Inc., in India. The board at its meeting held on January 05, 2012 has discussed and approved for the same.
Further, the implementation of the above proposal would be subject to various approvals and permissions.
Recently, Pfizer had recalled Citalopram tablets, from the US market owing to wrong labeling. Citalopram tablets were manufactured by city-based Aurobindo Pharma. The latest recall, which was notified by the USFDA on August 17, involved 720 units of Citalopram tablets, USP, 10 mg, 100-count bottles.
Pfizer, a subsidiary of Pfizer Inc, is engaged in manufacturing of products like Protinex, Isonex, Becosules and Corex.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.10 |
| Dr. Reddys Lab | 1279.30 |
| Cipla | 1342.10 |
| Zydus Lifesciences | 937.00 |
| Lupin | 2292.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: